Meridiem Investment Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-350
Closed -$21K 76
2021
Q4
$21K Hold
350
﹤0.01% 69
2021
Q3
$15K Hold
350
﹤0.01% 71
2021
Q2
$14K Hold
350
﹤0.01% 70
2021
Q1
$13K Sell
350
-3,810
-92% -$135K ﹤0.01% 73
2020
Q4
$153K Buy
+4,160
New +$153K 0.01% 53

Other funds holding PFE

Meridiem Investment Management's PFE Position: Q1 2022 in Review

Meridiem Investment Management sold out of Pfizer (PFE) in Q1 2022, closing a stake of 350 shares — an estimated $21K sold.

Meridiem Investment Management first reported a position in PFE in Q4 2020 and held it in 5 quarters. The position peaked at $153K in Q4 2020. 3,195 funds tracked by Wall St. Rank hold PFE as of Q1 2022.

  • Meridiem Investment Management reported no remaining Pfizer position as of Q1 2022 after selling out during the quarter.
  • Meridiem Investment Management sold 350 Pfizer shares in Q1 2022, an estimated $21K.
  • Meridiem Investment Management first reported a position in Pfizer in Q4 2020 and held it in 5 quarters.
  • Meridiem Investment Management's Pfizer position peaked at $153K in Q4 2020.
  • 3,195 funds tracked by Wall St. Rank held Pfizer as of Q1 2022.

Based on Meridiem Investment Management's 13F filing for Q1 2022, filed 16 May 2022.